Abstract
Monoclonal antibodies are currently the most attractive therapeutic modality in a broad range of disease areas, including infectious diseases, autoimmune diseases, and oncology. Fc engineering is one attractive application to maximize the value or overcome the drawbacks of monoclonal antibodies for therapeutic use. With the Fc region, antibodies bind to several types of receptors, such as Fc gamma receptors, a complement receptor, and a neonatal Fc receptor. Through this interaction with the receptors, antibodies demonstrate unique functions, such as antibody-dependent cellular cytotoxicity, antibody- dependent cellular phagocytosis, complement dependent cytotoxicity, agonistic activity, and endosomal recycling. Fc engineering technology is conducted mainly to maximize the receptor-mediated functions of antibodies. Moreover, Fc engineering of the two heavy chains to facilitate heterodimerization is indispensable for generating IgG-like bispecific antibodies that are asymmetric. Fc engineering is also conducted to avoid the undesired properties, such as cytokine release and protease-mediated cleavage of the hinge region, of wild-type antibodies, as well as providing additional functions. Thus, Fc engineering technology is an attractive approach for maximizing the potency and convenience of therapeutic antibodies. This review will cover a variety of Fc engineering technologies that improve the functions of therapeutic antibodies.
Keywords: Antibody engineering, therapeutic antibody, Fc engineering, antibody, protein engineering.
Current Pharmaceutical Biotechnology
Title:Fc Engineering to Improve the Function of Therapeutic Antibodies
Volume: 17 Issue: 15
Author(s): Futa Mimoto, Taichi Kuramochi, Hitoshi Katada, Tomoyuki Igawa and Kunihiro Hattori
Affiliation:
Keywords: Antibody engineering, therapeutic antibody, Fc engineering, antibody, protein engineering.
Abstract: Monoclonal antibodies are currently the most attractive therapeutic modality in a broad range of disease areas, including infectious diseases, autoimmune diseases, and oncology. Fc engineering is one attractive application to maximize the value or overcome the drawbacks of monoclonal antibodies for therapeutic use. With the Fc region, antibodies bind to several types of receptors, such as Fc gamma receptors, a complement receptor, and a neonatal Fc receptor. Through this interaction with the receptors, antibodies demonstrate unique functions, such as antibody-dependent cellular cytotoxicity, antibody- dependent cellular phagocytosis, complement dependent cytotoxicity, agonistic activity, and endosomal recycling. Fc engineering technology is conducted mainly to maximize the receptor-mediated functions of antibodies. Moreover, Fc engineering of the two heavy chains to facilitate heterodimerization is indispensable for generating IgG-like bispecific antibodies that are asymmetric. Fc engineering is also conducted to avoid the undesired properties, such as cytokine release and protease-mediated cleavage of the hinge region, of wild-type antibodies, as well as providing additional functions. Thus, Fc engineering technology is an attractive approach for maximizing the potency and convenience of therapeutic antibodies. This review will cover a variety of Fc engineering technologies that improve the functions of therapeutic antibodies.
Export Options
About this article
Cite this article as:
Mimoto Futa, Kuramochi Taichi, Katada Hitoshi, Igawa Tomoyuki and Hattori Kunihiro, Fc Engineering to Improve the Function of Therapeutic Antibodies, Current Pharmaceutical Biotechnology 2016; 17 (15) . https://dx.doi.org/10.2174/1389201017666160824161854
DOI https://dx.doi.org/10.2174/1389201017666160824161854 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Unique Phenotypes and Functions of Follicular Helper T Cells and Regulatory T Cells in Sjögren’s Syndrome
Current Rheumatology Reviews Emerging Treatment Strategies and Potential Therapeutic Targets in Primary Sjogrens Syndrome
Inflammation & Allergy - Drug Targets (Discontinued) Hot topic: Editorial [Therapeutic Potential of Peptide Motifs - Part IV] (Jean Claude Herve)
Current Pharmaceutical Design Recent Advances in Improving Sub-Unit Vaccine Efficacy Using Cytokines as more Specific Immune Inducing Adjuvants
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Statins Therapy for Connective Tissue Diseases: New Therapeutic Opportunities
Endocrine, Metabolic & Immune Disorders - Drug Targets Chaperonopathies and Chaperonotherapy. Hsp60 as Therapeutic Target in Cancer: Potential Benefits and Risks
Current Pharmaceutical Design Oral Tolerance in the Treatment of Rheumatoid Arthritis
Current Drug Targets - Inflammation & Allergy Triggering of Apoptosis and Pro-Inflammatory Cytokines in NK Cells: Regulation by Cyclosporin A
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Juvenile Systemic Lupus Erythematosus
Current Pediatric Reviews Invariant Natural Killer T Cell-Based Therapy of Autoimmune Diseases
Current Immunology Reviews (Discontinued) CD4+CD25+ Regulatory T-Cell Therapy for Allergy, Autoimmune Disease and Transplant Rejection
Inflammation & Allergy - Drug Targets (Discontinued) Circulating Matrix Metalloproteinase-9 Levels in Patients with Systemic Lupus Erythematosus: A Meta-analysis
Current Pharmaceutical Design Update on Intravenous Immunoglobulins (IVIg) Mechanisms of Action and Off- Label use in Autoimmune Diseases
Current Pharmaceutical Design Discovery of Small Molecule Inhibitors for Prevention of Complement- Mediated Immune Hemolysis
Drug Design Reviews - Online (Discontinued) Small Molecular Inhibitors for the Treatment of Rheumatoid Arthritis: Progress so Far
Mini-Reviews in Medicinal Chemistry B Cell Modulation Strategies in Autoimmunity: The SLE Example
Current Pharmaceutical Design Mouse Models of Autoimmune Diseases
Current Drug Discovery Technologies Defective Autophagy in Fibroblasts May Contribute to Fibrogenesis in Autoimmune Processes
Current Pharmaceutical Design Cytokines as Novel Therapeutic Agents for Neuroinflammatory Disorders: A Role for Interferon-β in the Treatment of Multiple Sclerosis
Current Medicinal Chemistry - Central Nervous System Agents Stem Cell-Based Therapies and Immunomodulatory Approaches in Newly Diagnosed Type 1 Diabetes
Current Stem Cell Research & Therapy